| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $118,856,644 ) (Continued on the next page) |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R50CA265182 | Molecular origins and evolution to treatment resistance in genitourinary cancers | 000 | 1 | NIH | 7/13/2022 | $330,413 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA259621 | Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer | 000 | 1 | NIH | 6/15/2022 | $211,308 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA273043 | Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention | 000 | 1 | NIH | 6/21/2022 | $255,792 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R35GM142527 | Mechanisms of eIF3-mediated translation regulation | 000 | 1 | NIH | 6/8/2022 | $13,573 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R35GM142527 | Mechanisms of eIF3-mediated translation regulation | 001 | 2 | NIH | 7/27/2022 | $445,000 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | UH3CA240688 | Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors | 000 | 3 | NIH | 4/19/2022 | $364,709 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00EB030587 | Interrogating and rewiring cell signaling pathways in CAR-T cells with synthetic phosphotyrosine recognition domains | 000 | 3 | NIH | 5/4/2022 | $249,000 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R03CA262839 | Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC) | 000 | 1 | NIH | 7/7/2022 | $89,000 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA262462 | Synthetic lethalities to cell cycle disruption in glioma | 000 | 1 | NIH | 5/13/2022 | $668,921 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA259538 | A Novel Intervention for Avoidance-Related Opioid Misuse in Patients with Cancer | 000 | 1 | NIH | 6/28/2022 | $152,737 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K99HL163396 | Mechanistic Understanding of Hypoxia-Induced Peroxisome loss: Implications for Heart Failure | 000 | 1 | NIH | 5/26/2022 | $149,850 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00GM135519 | De novo design of small-molecule-binding proteins | 000 | 3 | NIH | 8/12/2022 | $249,000 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA261863 | STEP-YA: An Online Self-Management Intervention for Young Adult Cancer Survivors with Insomnia | 000 | 1 | NIH | 5/27/2022 | $245,640 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA256644 | Prolonged Nightly Fasting as a Behavioral Intervention for Obesity Reduction and the Prevention of Progression in Precursor Multiple Myeloma | 000 | 1 | NIH | 6/2/2022 | $208,038 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA264900 | Elucidating the molecular mechanism and physiological relevance of TIRR mediated inhibition of p53 | 000 | 1 | NIH | 7/1/2022 | $389,982 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA267857 | Sleep Treatment Education Program-1 (STEP-1): A Randomized Trial of a Self-Management Insomnia Intervention for Cancer Survivors | 000 | 1 | NIH | 6/30/2022 | $249,645 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K00CA253738 | Perturbation based single cell investigation of tumor micro-environment | 000 | 3 | NIH | 8/8/2022 | $85,780 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA265826 | Dana Farber/Harvard Cancer Center SPORE in Lung Cancer | 001 | 1 | NIH | 8/4/2022 | $0 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | P50CA265826 | Dana Farber/Harvard Cancer Center SPORE in Lung Cancer | 000 | 1 | NIH | 7/29/2022 | $2,336,838 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA273123 | Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies | 000 | 1 | NIH | 7/22/2022 | $433,679 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 000 | 1 | NIH | 2/24/2022 | $525,969 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K00CA245819 | Investigating Immune Responses to Neoantigen Cancer Vaccines using In Vivo Functionalized Lineage | 000 | 3 | NIH | 1/31/2022 | $85,860 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00DK123321 | Mechanistic characterization of the anti-inflammatory function of thermogenic fat for the treatment of metabolic disorders | 001 | 3 | NIH | 6/10/2022 | $41,655 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00DK123321 | Mechanistic characterization of the anti-inflammatory function of thermogenic fat for the treatment of metabolic disorders | 000 | 3 | NIH | 1/22/2022 | $249,000 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA267527 | Defining the impact of mutational drivers on the immune microenvironment of CLL | 001 | 1 | NIH | 2/1/2022 | $109,395 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA267527 | Defining the impact of mutational drivers on the immune microenvironment of CLL | 000 | 1 | NIH | 1/31/2022 | $140,250 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00CA245899 | Deep clinical trajectory modeling to optimize accrual to cancer clinical trials | 001 | 3 | NIH | 5/31/2022 | $2,570 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00CA245899 | Deep clinical trajectory modeling to optimize accrual to cancer clinical trials | 002 | 3 | NIH | 7/12/2022 | -$248,999 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00CA245899 | Deep clinical trajectory modeling to optimize accrual to cancer clinical trials | 002 | 3 | NIH | 7/12/2022 | $248,999 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R00CA245899 | Deep clinical trajectory modeling to optimize accrual to cancer clinical trials | 000 | 3 | NIH | 2/3/2022 | $248,999 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA267138 | Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression | 000 | 1 | NIH | 2/4/2022 | $232,259 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA270069 | Development of A Mindfulness-Based Mobile Health Intervention for Patients Coping with Pain from Advanced Malignancies | 000 | 1 | NIH | 3/31/2022 | $264,825 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01DK132544 | Engineering dendritic cells to target islet antigen to pro-tolerogenic subsets for prevention and treatment of Type 1 Diabetes | 000 | 1 | NIH | 3/22/2022 | $445,000 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 000 | 1 | NIH | 1/19/2022 | $680,864 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01HL157174 | Systematic identification of minor histocompatibility antigens to address GVHD | 000 | 1 | NIH | 3/23/2022 | $760,557 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA265928 | A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies | 000 | 1 | NIH | 3/1/2022 | $713,250 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K00CA253731 | Targeting Oncogenic Drivers in Cancer | 000 | 3 | NIH | 3/1/2022 | $85,860 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K99CA267082 | Modeling and Dissecting Epigenetic Drivers of Gliomagenesis | 000 | 1 | NIH | 2/15/2022 | $167,400 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA259200 | Genomic Diversity of Prostate Cancer Across the African Diaspora | 000 | 1 | NIH | 1/7/2022 | $1,324,467 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA267107 | Novel Health Equity Intervention to Improve Pediatric Oncology Outcome Disparities: Targeting Poverty and Psychosocial Stress | 000 | 1 | NIH | 2/11/2022 | $651,395 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 1 | NIH | 11/22/2021 | $1,238,693 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | UM1HG011989 | Molecular phenotyping of ~100,000 coding variants across Mendelian disease genes | 000 | 2 | NIH | 5/31/2022 | $1,848,399 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01HG011928 | A Stakeholder Informed Randomized Trial of Pretest Video Education vs Standard Genetic Counseling for Cancer Patients: Evaluating the Impact on Patients, Providers and Practices | 001 | 2 | NIH | 6/24/2022 | $838,005 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA249185 | Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications | 000 | 2 | NIH | 7/19/2022 | $405,748 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | K08CA252169 | Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer | 000 | 2 | NIH | 6/30/2022 | $208,829 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 001 | 2 | NIH | 5/25/2022 | $32,574 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 000 | 2 | NIH | 3/24/2022 | $366,458 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R01AI155796 | Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency | 000 | 2 | NIH | 5/12/2022 | $441,100 |
| | 2022 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02115-5418 | SUFFOLK | USA | R21CA263130 | Targeting the DNA Damage Response in CDK12-Mutant Prostate Cancer | 000 | 2 | NIH | 6/23/2022 | $243,938 |
|
